VOR
Price:
$0.8745
Market Cap:
$60.06M
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge...[Read more]
Industry
Biotechnology
IPO Date
2021-02-05
Stock Exchange
NASDAQ
Ticker
VOR
According to Vor Biopharma Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.53. This represents a change of -42.86% compared to the average of -0.93 of the last 4 quarters.
The mean historical PE Ratio of Vor Biopharma Inc. over the last ten years is -35.89. The current -0.53 PE Ratio has changed 47.69% with respect to the historical average. Over the past ten years (40 quarters), VOR's PE Ratio was at its highest in in the September 2019 quarter at -0.26. The PE Ratio was at its lowest in in the December 2019 quarter at -29.40.
Average
-35.89
Median
-19.20
Minimum
-121.60
Maximum
-1.28
Discovering the peaks and valleys of Vor Biopharma Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 137.86%
Maximum Annual PE Ratio = -1.28
Minimum Annual Increase = -80.45%
Minimum Annual PE Ratio = -121.60
Year | PE Ratio | Change |
---|---|---|
2023 | -1.28 | -55.73% |
2022 | -2.90 | -53.86% |
2021 | -6.28 | -80.45% |
2020 | -32.13 | -73.58% |
2019 | -121.60 | 137.86% |
The current PE Ratio of Vor Biopharma Inc. (VOR) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-3.49
5-year avg
-32.84
10-year avg
-35.89
Vor Biopharma Inc.’s PE Ratio is greater than Gracell Biotechnologies Inc. (-29.26), greater than Theseus Pharmaceuticals, Inc. (-6.29), greater than Monte Rosa Therapeutics, Inc. (-4.84), greater than Design Therapeutics, Inc. (-7.53), greater than Erasca, Inc. (-4.56), greater than Edgewise Therapeutics, Inc. (-22.36), greater than Talaris Therapeutics, Inc. (-11.29), greater than Adicet Bio, Inc. (-0.71), greater than Cullinan Oncology, Inc. (-4.99), greater than Nuvalent, Inc. (-24.20), greater than Ventyx Biosciences, Inc. (-1.05), greater than Arcellx, Inc. (-103.30), greater than Kiniksa Pharmaceuticals, Ltd. (-157.72), less than Bolt Biotherapeutics, Inc. (-0.30), greater than Day One Biopharmaceuticals, Inc. (-14.52), less than Lyra Therapeutics, Inc. (-0.12), greater than Autolus Therapeutics plc (-2.22), greater than Foghorn Therapeutics Inc. (-3.45), greater than Shattuck Labs, Inc. (-0.76), greater than Kymera Therapeutics, Inc. (-18.55), greater than Nurix Therapeutics, Inc. (-8.05),
Company | PE Ratio | Market cap |
---|---|---|
-29.26 | $989.87M | |
-6.29 | $181.50M | |
-4.84 | $433.13M | |
-7.53 | $359.54M | |
-4.56 | $726.61M | |
-22.36 | $2.80B | |
-11.29 | $116.44M | |
-0.71 | $75.50M | |
-4.99 | $714.45M | |
-24.20 | $5.87B | |
-1.05 | $160.51M | |
-103.30 | $4.20B | |
-157.72 | $1.44B | |
-0.30 | $19.63M | |
-14.52 | $1.28B | |
-0.12 | $11.28M | |
-2.22 | $598.77M | |
-3.45 | $279.08M | |
-0.76 | $52.99M | |
-18.55 | $2.64B | |
-8.05 | $1.39B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Vor Biopharma Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Vor Biopharma Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Vor Biopharma Inc.'s PE Ratio?
How is the PE Ratio calculated for Vor Biopharma Inc. (VOR)?
What is the highest PE Ratio for Vor Biopharma Inc. (VOR)?
What is the 3-year average PE Ratio for Vor Biopharma Inc. (VOR)?
What is the 5-year average PE Ratio for Vor Biopharma Inc. (VOR)?
How does the current PE Ratio for Vor Biopharma Inc. (VOR) compare to its historical average?